HCW Biologics Inc.
HCWB
$7.05
-$0.58-7.60%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -70.18% | -50.02% | -0.63% | 2,589.02% | -1.30% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -70.18% | -50.02% | -0.63% | 2,589.02% | -1.30% |
| Cost of Revenue | -70.52% | -49.71% | -12.74% | 1,641.50% | -0.17% |
| Gross Profit | -68.73% | -51.20% | 49.83% | 4,817.60% | -5.85% |
| SG&A Expenses | -60.53% | -27.52% | 295.63% | 91.39% | 193.59% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -59.85% | -30.59% | 181.59% | 59.56% | 72.53% |
| Operating Income | 58.58% | 27.33% | -206.75% | -39.79% | -90.01% |
| Income Before Tax | 68.42% | 20.98% | -254.99% | -47.28% | -97.10% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 68.42% | 20.98% | -254.99% | -47.28% | -97.10% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 68.42% | 20.98% | -254.99% | -47.28% | -97.10% |
| EBIT | 58.58% | 27.33% | -206.75% | -39.79% | -90.01% |
| EBITDA | 64.00% | 25.80% | -224.31% | -43.24% | -89.61% |
| EPS Basic | 73.14% | 24.95% | -236.95% | -41.97% | -96.36% |
| Normalized Basic EPS | 62.78% | 24.91% | -208.41% | -38.87% | -93.93% |
| EPS Diluted | 73.14% | 24.95% | -236.95% | -41.97% | -90.31% |
| Normalized Diluted EPS | 62.78% | 24.91% | -208.41% | -38.87% | -93.93% |
| Average Basic Shares Outstanding | 17.52% | 5.28% | 5.33% | 3.73% | 0.38% |
| Average Diluted Shares Outstanding | 17.52% | 5.28% | 5.33% | 3.73% | 0.38% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |